JACKSONVILLE, Fla., Oct. 17, 2005 (PRIMEZONE) -- Phlo Corporation (Pink Sheets:PHLC) ("Phlo") announced today that one of its affiliates (the "Company") has received an initial order for its AQUIS(tm) Rapid Response Rehydration product line from the Athletic Department of Lehigh University. Located in Bethlehem, Pennsylvania, Lehigh conducts 25 NCAA Division I intercollegiate men's and women's sports and competes in the Patriot League with schools such as Army and Navy. Lehigh recently was ranked 32nd in U.S. News and World Report's "2006 America's Best Colleges" survey.
AQUIS(tm) Rapid Response Rehydration solutions are based on the Company's patent-pending MEDS (Micro-Encapsulation Delivery System) technology which allows for immediate absorption of the electrolyte payload into the bloodstream, beginning through the mucous membranes of the mouth. This micro-encapsulation of the electrolytes allows AQUIS(tm) to taste good (no salty taste), encouraging consumption prior to the point of dehydration.
The Company plans to continue to announce further developments on the sales front, including purchases of AQUIS(tm) by additional colleges and universities as such purchases occur.
Phlo also announced today that on October 12, 2005, it filed with the Securities and Exchange Commission its Form 10-QSB for the fiscal quarter ended December 31, 2004. Phlo is continuing its efforts to become completely current in its filings and believes that it will accomplish that goal in the very near future. However, Phlo cannot make any assurances with respect to the exact dates upon which such filings will be made due to factors normally associated with such a process, which are not under the control of Phlo.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patents-pending biotechnologies which are sold on a commercial basis to governmental and institutional purchasers and to high volume chain stores, such as supermarkets and drug and convenience stores. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historical constitute "forward-looking" statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as "anticipate," "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation's control. Actual results may differ materially from the statements set forth above.